ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Proteases >Proteasome inhibitors >MLN9708

MLN9708

CAS No.: 1201902-80-8

Chemical Name:: MLN9708

Synonyms: MLN9708;CS-1830;Ninlaro);MLN-9708 analog;MLN 9708 analog;MLN9708;MLN-9708;Ixazomib Citrate;Esazomide citrate;MLN9708,MLN-9708,MLN 9708;MLN 9708 - Ixazomib citrate

CBNumber:: CB82521079

Molecular Formula:: C20H23BCl2N2O9

Molecular Weight:: 517.12

MOL File:: 1201902-80-8.mol

MSDS File:: SDS

Modify Date:: 2023/6/8 9:02:27

Request For Quotation

MLN9708 Properties

Melting point	>227°C (dec.)
Density	1.47
storage temp.	Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility	DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
pka	1.92±0.20(Predicted)
form	Solid
color	White to Off-White

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07

Signal word

Warning

Hazard statements

H302-H315-H319-H335

Precautionary statements

P261-P305+P351+P338

Safety Statements

24/25

HS Code

29329990

NFPA 704

	0
2		0

MLN9708 Chemical Properties,Uses,Production

Description

Ixazomib citrate is a proteasome inhibitor prodrug for the treatment of multiple myeloma in patients who have received at least one prior therapy in combination with lenalidomide and dexamethasone. The drug was developed by Takeda and reversibly inhibits the protein proteasome subunit β type-5, which is part of the 20S proteasome complex. Ixazomib citrate (XXIV) is hydrolyzed quickly in vivo to give the biologically active compound ixazomib, which presumably is the corresponding boronic acid variant of XXIV.

Uses

MLN-9708 is a novel proteasome?inhibitor.

Synthesis

The structure of ixazomib citrate is particularly interesting in that it is one of the relatively few marketed drugs which feature a boron atom within its structure (others of note being the oncology medication bortezomib and the antifungal drug tavaborole13). The ostensible scale synthetic approach began with reaction of commercial 2,5-dichlorobenzoyl chloride (188) with glycine in aqueous NaOH to furnish amide 189 in 97% yield as a white crystalline solid. Acid 189 was then coupled with commercially available 1,3,2-benzodioxaborolane 190 in the presence of TBTU and DIPEA in DMF at low temperature to give diamide 191, which was used without purification for the next step. Borane 191 was then deprotected with (2-methylpropyl)boronic acid in methanolic HCl to provide trimer 192 in 74% as a white solid. Finally, boroxin 192 was reacted with citric acid in EtOAc to dissociate the trimer, resulting in ixazomib citrate (XXIV) in 88% yield as a crystalline solid.

Synthesis_1201902-80-8

MLN9708 Preparation Products And Raw materials

Raw materials

Preparation Products

MLN9708 Suppliers

Global( 180)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
AKASH PHARMA EXPORTS	+91-9388123451 +91-9846039283	Kerela, India	470	58	Inquiry
MSN LABORATORIES PRIVATE LTD	+91 40 30438600	New Delhi, India	230	58	Inquiry
SUN PHARMACEUTICAL INDUSTRIES LTD	(+91 22) 4324 4324	New Delhi, India	175	58	Inquiry
A.J Chemicals	91-9810153283	New Delhi, India	6124	58	Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd	+91-172-5066494	Haryana, India	6773	58	Inquiry
Alpha Biopharmaceuticals Co., Ltd	+86-15542445688	China	888	58	Inquiry
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	China	32760	60	Inquiry
career henan chemical co	+86-0371-86658258 +8613203830695	China	29898	58	Inquiry
Chongqing Chemdad Co., Ltd	+86-023-6139-8061 +86-86-13650506873	China	39916	58	Inquiry
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	United States	19892	58	Inquiry

Supplier	Advantage
AKASH PHARMA EXPORTS	58
MSN LABORATORIES PRIVATE LTD	58
SUN PHARMACEUTICAL INDUSTRIES LTD	58
A.J Chemicals	58
Pharmaffiliates Analytics and Synthetics P. Ltd	58
Alpha Biopharmaceuticals Co., Ltd	58
ATK CHEMICAL COMPANY LIMITED	60
career henan chemical co	58
Chongqing Chemdad Co., Ltd	58
TargetMol Chemicals Inc.	58

MLN9708 Spectrum

MLN9708(1201902-80-8)¹HNMR

1201902-80-8(MLN9708)Related Search:

Pevonedistat MLN-4760 MLN-8237 Ixazomib Impurity 1 Ixazomib citrate (USAN)

Acetamide, 2-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]- NS-398 Acid resistant proteinase CANGRELOR Azilsartan

Tigecycline Pazopanib Boric acid Bortezomib (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid

Oprozomib CEP-18770 ABT 263

chevron_left

1of4

chevron_right

4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid MLN9708 MLN9708,MLN-9708,MLN 9708 4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid 4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid MLN9708 Ixazomib Citrate MLN9708;MLN-9708 4-(Carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dio MLN 9708 analog MLN-9708 analog 4-(carboxymethyl)-2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid MLN 9708 - Ixazomib citrate CS-1830 MLN9708, 98%, 20S proteasome inhibitor 1,3,2-Dioxaborinane-4-acetic acid, 4-carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo- Ninlaro) Esazomide citrate Ixazomib Citrate (MLN9708) Analogue 1201902-80-8 C20H23BCl2N2O9 Inhibitors Inhibitor Apis